Compare Kingsoft Cloud Holdings Limited (KC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kingsoft Cloud Holdings Limited vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Kingsoft Cloud Holdings Limited trades at $8.58 (market cap $2.77B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Kingsoft Cloud Holdings Limited is far larger — about 2.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kingsoft Cloud Holdings Limited for 12 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| KC | MRVI | |
|---|---|---|
Market Cap | $2.77B | $972.90M |
Volume | 986,009 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $18.21 | $9.00 |
52-Week Low | $8.58 | $2.83 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $3.10B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kingsoft Cloud (KC) trades at $9.32, up 0.76% with a bearish technical signal despite recent earnings beats. The company shows improving revenue trends ($11.0B projected for 2026) and significant AI cloud growth, though profitability remains negative with -5.46% net margin. Analyst sentiment is strongly positive with 70% buy ratings and 60.25% upside potential cited.
KC presents a high-risk, high-reward opportunity with strong AI-driven growth potential but persistent profitability challenges. The stock's appeal hinges on continued AI cloud expansion and margin improvement, though investors face execution risks and Chinese regulatory exposure. Wall Street optimism contrasts with current technical weakness.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
